{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:27:30Z","timestamp":1791034050832,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.bcp.2007.01.027","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T15:04:55Z","timestamp":1169737495000},"page":"1573-1581","source":"Crossref","is-referenced-by-count":132,"title":["Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein"],"prefix":"10.1016","volume":"73","author":[{"given":"Caroline Henrike","family":"Storch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Lindenmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Emil","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2007.01.027_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003088-200342030-00002","article-title":"Drug interactions between antiretroviral drugs and comedicated agents","volume":"42","author":"De Maat","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bcp.2007.01.027_bib2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJM200103293441307","article-title":"Interactions among drugs for HIV and opportunistic infections","volume":"344","author":"Piscitelli","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2007.01.027_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/135965350200600401","article-title":"Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetic and clinical experience","volume":"6","author":"Van Heeswijk","year":"2001","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bcp.2007.01.027_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200544020-00001","article-title":"Interactions between antiretrovirals and antineoplastic drug therapy","volume":"44","author":"Antoniou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bcp.2007.01.027_bib5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.48.4.1073-1081.2004","article-title":"P-glycoprotein in human immunodeficiency virus type 1 infection and therapy","volume":"48","author":"Sankatsing","year":"2004","journal-title":"Antimicrob Agents Ther"},{"key":"10.1016\/j.bcp.2007.01.027_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00007691-200112000-00001","article-title":"Pharmacokinetic and other drug interactions in patients with AIDS","volume":"23","author":"Dasgupta","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bcp.2007.01.027_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bcp.2007.01.027_bib8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/00912709922012006","article-title":"The contribution of P-glycoprotein to pharmacokinetic drug\u2013drug interactions","volume":"39","author":"Yu","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib9","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/bi972709x","article-title":"HIV-1 Protease inhibitors are substrates for the MDR1 multidrug transporter","volume":"37","author":"Lee","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2007.01.027_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/00002030-199909100-00004","article-title":"Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors","volume":"13","author":"Profit","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2007.01.027_bib11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1124\/mol.59.4.806","article-title":"P-glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir","volume":"59","author":"Huisman","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib12","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jps.1133","article-title":"Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line","volume":"90","author":"Perloff","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bcp.2007.01.027_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1124\/dmd.104.002931","article-title":"Atazanavir: effects on P-Glycoprotein transport and CYP3A metabolism in vitro","volume":"33","author":"Perloff","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2007.01.027_bib14","first-page":"754","article-title":"Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors","volume":"29","author":"Huang","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2007.01.027_bib15","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1128\/AAC.49.12.4903-4910.2005","article-title":"Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers","volume":"49","author":"Mukwaya","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2007.01.027_bib16","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1177\/009127000004001226","article-title":"A study of the pharmacokinetics of azithromycin and nelfinavir when coadministerd in healthy volunteers","volume":"40","author":"Amsden","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clpt.2004.02.008","article-title":"Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers","volume":"76","author":"Ding","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2007.01.027_bib18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1023\/A:1016430825740","article-title":"Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture","volume":"19","author":"Stormer","year":"2002","journal-title":"Pharm Res"},{"key":"10.1016\/j.bcp.2007.01.027_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00126334-200308150-00001","article-title":"The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro","volume":"33","author":"Chandler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bcp.2007.01.027_bib20","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1089\/aid.1992.8.1839","article-title":"Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein","volume":"8","author":"Antonelli","year":"1992","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.bcp.2007.01.027_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1139\/y99-059","article-title":"Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs","volume":"77","author":"Leung","year":"1999","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/135965350400900403","article-title":"ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages","volume":"9","author":"Jorajuria","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bcp.2007.01.027_bib23","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2007.01.027_bib24","series-title":"Poster 49, International Workshop on Clinical Pharmacology of HIV Therapy","article-title":"Role of intestinal absorption in increased tenofovir exposure when tenofovir disoproxil fumarate is co-administered with atazanavir or lopinavir\/ritonavir","author":"Ray","year":"2006"},{"key":"10.1016\/j.bcp.2007.01.027_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/dmd.30.8.924","article-title":"Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures","volume":"30","author":"Van Gelder","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2007.01.027_bib26","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1172\/JCI118214","article-title":"Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A","volume":"96","author":"Schinkel","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2007.01.027_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/jpet.102.046532","article-title":"Inhibition of P-glycoprotein by newer antidepressants","volume":"305","author":"Weiss","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2007.01.027_bib28","first-page":"4226","article-title":"In vivo circumvention of P-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC 833","volume":"51","author":"Boesch","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2007.01.027_bib29","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.bcp.2004.08.026","article-title":"In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins","volume":"68","author":"Fr\u00f6hlich","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bcp.2005.06.018","article-title":"Expression of the drug transporters MDR1\/ABCB1, MRP1\/ABCC1, MRP2\/ABCC2, BCRP\/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver","volume":"70","author":"Albermann","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/dmd.105.007377","article-title":"Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: F2 values","volume":"34","author":"Weiss","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2007.01.027_bib32","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1248\/bpb.23.1528","article-title":"Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins","volume":"23","author":"Shiraki","year":"2000","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bcp.2007.01.027_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00042560-199811010-00001","article-title":"Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells","volume":"19","author":"Washington","year":"1998","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bcp.2007.01.027_bib34","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/00002030-200203080-00024","article-title":"Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors","volume":"16","author":"Weiss","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2007.01.027_bib35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11095-005-5271-y","article-title":"Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood\u2013brain barrier","volume":"22","author":"Bachmeier","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.bcp.2007.01.027_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00007691-200406000-00018","article-title":"Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes","volume":"26","author":"Penzak","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bcp.2007.01.027_bib37","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/00002030-200006160-00016","article-title":"Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir","volume":"14","author":"Van Praag","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2007.01.027_bib38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/0091270006288733","article-title":"Time-dependent interaction between lopinavir\/ritonavir and fexofenadine","volume":"46","author":"Van Heeswijk","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","article-title":"The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors","volume":"101","author":"Kim","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2007.01.027_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002030-200002180-00005","article-title":"Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors","volume":"14","author":"Huisman","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2007.01.027_bib41","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/01.aids.0000194793.36175.40","article-title":"Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP","volume":"19","author":"Janneh","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2007.01.027_bib42","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dki308","article-title":"Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals","volume":"56","author":"Almond","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2007.01.027_bib43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1021\/js970291i","article-title":"In vitro blood\u2013brain barrier permeability of nevirapine compared to other HIV antiretroviral agents","volume":"87","author":"Glynn","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bcp.2007.01.027_bib44","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s11095-006-0279-5","article-title":"Efavirenz does not interact with the ABCB1 transporter at the blood\u2013brain barrier","volume":"23","author":"Dirson","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.bcp.2007.01.027_bib45","first-page":"226","article-title":"Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats","volume":"8","author":"Berruet","year":"2005","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.bcp.2007.01.027_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/00912700122009728","article-title":"Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors","volume":"41","author":"Von Moltke","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0005-2736(94)90190-2","article-title":"Calcein accumulation as fluorometric assay of th43e multidrug transporter","volume":"1191","author":"Holl\u00f3","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2007.01.027_bib48","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/bjc.1996.151","article-title":"A new method for quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells","volume":"73","author":"Homolya","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bcp.2007.01.027_bib49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/bjc.1995.371","article-title":"Functional detection of MDR1\/P170 and MRP\/P190-mediated multidrug resistance in tumour cells by flow cytometry","volume":"72","author":"Feller","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bcp.2007.01.027_bib50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/002215540205000514","article-title":"The fluorescent probe bodipy-FL-verapamil is a substrate for both P-glycoprotein and multidrug resistance protein (MRP)-1","volume":"50","author":"Crivellato","year":"2002","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.bcp.2007.01.027_bib51","first-page":"6635","article-title":"Acquired mutations in the MXR\/BCRP\/ABCP gene alter substrate specificity in MXR\/BCRP\/ABCP-over-expressing cells","volume":"61","author":"Honjo","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2007.01.027_bib52","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1124\/mol.64.6.1452","article-title":"Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis","volume":"64","author":"Nakanishi","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2007.01.027_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0928-0987(00)00097-X","article-title":"Specifity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein function in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines","volume":"11","author":"Van der Sandt","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bcp.2007.01.027_bib54","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1242\/jcs.113.11.2011","article-title":"The multidrug-resistant phenotype associated with over-expression of the new ABC half-transporter MXR (ABCG2)","volume":"113","author":"Litman","year":"2000","journal-title":"J Cell Sci"},{"key":"10.1016\/j.bcp.2007.01.027_bib55","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1073\/pnas.85.12.4486","article-title":"A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells","volume":"85","author":"Pastan","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2007.01.027_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bcp.2003.09.008","article-title":"Influence of lipid lowering fibrates on P-glycoprotein activity in vitro","volume":"67","author":"Ehrhardt","year":"2004","journal-title":"Biochem Pharmacol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295207000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295207000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:26:00Z","timestamp":1683728760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295207000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0006295207000615"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2007.01.027","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}